AU2019285065A1 - Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration - Google Patents
Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration Download PDFInfo
- Publication number
- AU2019285065A1 AU2019285065A1 AU2019285065A AU2019285065A AU2019285065A1 AU 2019285065 A1 AU2019285065 A1 AU 2019285065A1 AU 2019285065 A AU2019285065 A AU 2019285065A AU 2019285065 A AU2019285065 A AU 2019285065A AU 2019285065 A1 AU2019285065 A1 AU 2019285065A1
- Authority
- AU
- Australia
- Prior art keywords
- aminosterol
- dose
- subject
- derivative
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 199
- 230000004770 neurodegeneration Effects 0.000 title claims abstract description 116
- 239000000203 mixture Substances 0.000 title claims description 69
- WUJVPODXELZABP-FWJXURDUSA-N trodusquemine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCNCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 WUJVPODXELZABP-FWJXURDUSA-N 0.000 claims abstract description 255
- 150000003839 salts Chemical class 0.000 claims abstract description 153
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 70
- 230000012010 growth Effects 0.000 claims abstract description 55
- 230000032683 aging Effects 0.000 claims abstract description 51
- 201000010099 disease Diseases 0.000 claims abstract description 36
- 239000008194 pharmaceutical composition Substances 0.000 claims description 83
- 238000012360 testing method Methods 0.000 claims description 74
- 208000024891 symptom Diseases 0.000 claims description 58
- 230000035800 maturation Effects 0.000 claims description 49
- 208000019116 sleep disease Diseases 0.000 claims description 49
- 238000009472 formulation Methods 0.000 claims description 42
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 36
- 230000033001 locomotion Effects 0.000 claims description 35
- 208000035475 disorder Diseases 0.000 claims description 34
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 33
- 230000006872 improvement Effects 0.000 claims description 30
- 208000024827 Alzheimer disease Diseases 0.000 claims description 27
- 201000006417 multiple sclerosis Diseases 0.000 claims description 27
- 210000004556 brain Anatomy 0.000 claims description 25
- 230000001771 impaired effect Effects 0.000 claims description 24
- 208000018737 Parkinson disease Diseases 0.000 claims description 23
- 238000011282 treatment Methods 0.000 claims description 23
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 22
- 206010020772 Hypertension Diseases 0.000 claims description 21
- 230000003930 cognitive ability Effects 0.000 claims description 21
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 20
- 206010012289 Dementia Diseases 0.000 claims description 19
- 239000002552 dosage form Substances 0.000 claims description 19
- 238000003384 imaging method Methods 0.000 claims description 19
- 208000010877 cognitive disease Diseases 0.000 claims description 18
- 230000002596 correlated effect Effects 0.000 claims description 18
- 230000004064 dysfunction Effects 0.000 claims description 18
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 18
- 230000007958 sleep Effects 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 17
- 201000006474 Brain Ischemia Diseases 0.000 claims description 16
- 208000002177 Cataract Diseases 0.000 claims description 16
- 206010008118 cerebral infarction Diseases 0.000 claims description 16
- 230000000302 ischemic effect Effects 0.000 claims description 16
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 16
- 230000003340 mental effect Effects 0.000 claims description 16
- 210000003205 muscle Anatomy 0.000 claims description 16
- 208000001132 Osteoporosis Diseases 0.000 claims description 15
- 230000001149 cognitive effect Effects 0.000 claims description 15
- 230000007423 decrease Effects 0.000 claims description 15
- 230000003111 delayed effect Effects 0.000 claims description 15
- 208000022925 sleep disturbance Diseases 0.000 claims description 15
- 208000020685 sleep-wake disease Diseases 0.000 claims description 15
- 208000025535 REM sleep behavior disease Diseases 0.000 claims description 14
- 230000002159 abnormal effect Effects 0.000 claims description 14
- 206010002942 Apathy Diseases 0.000 claims description 13
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 13
- 206010010774 Constipation Diseases 0.000 claims description 13
- 201000004810 Vascular dementia Diseases 0.000 claims description 13
- 206010003246 arthritis Diseases 0.000 claims description 13
- 230000002490 cerebral effect Effects 0.000 claims description 13
- 208000031237 olivopontocerebellar atrophy Diseases 0.000 claims description 13
- 230000000750 progressive effect Effects 0.000 claims description 13
- 201000001320 Atherosclerosis Diseases 0.000 claims description 12
- 201000002832 Lewy body dementia Diseases 0.000 claims description 12
- 230000036541 health Effects 0.000 claims description 12
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 11
- 230000001934 delay Effects 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 11
- 208000028698 Cognitive impairment Diseases 0.000 claims description 10
- 206010019280 Heart failures Diseases 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 230000006399 behavior Effects 0.000 claims description 10
- 230000003542 behavioural effect Effects 0.000 claims description 10
- 230000008859 change Effects 0.000 claims description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 9
- 206010034010 Parkinsonism Diseases 0.000 claims description 9
- 238000004458 analytical method Methods 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 238000013270 controlled release Methods 0.000 claims description 9
- 208000029078 coronary artery disease Diseases 0.000 claims description 9
- 229940097496 nasal spray Drugs 0.000 claims description 9
- 239000007922 nasal spray Substances 0.000 claims description 9
- 239000003826 tablet Substances 0.000 claims description 9
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 8
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 claims description 8
- 208000032843 Hemorrhage Diseases 0.000 claims description 8
- 208000028226 Krabbe disease Diseases 0.000 claims description 8
- 208000031481 Pathologic Constriction Diseases 0.000 claims description 8
- 208000007536 Thrombosis Diseases 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 206010012601 diabetes mellitus Diseases 0.000 claims description 8
- 230000004060 metabolic process Effects 0.000 claims description 8
- 230000036262 stenosis Effects 0.000 claims description 8
- 208000037804 stenosis Diseases 0.000 claims description 8
- 208000019901 Anxiety disease Diseases 0.000 claims description 7
- 206010022998 Irritability Diseases 0.000 claims description 7
- 230000036506 anxiety Effects 0.000 claims description 7
- 238000002598 diffusion tensor imaging Methods 0.000 claims description 7
- 230000003291 dopaminomimetic effect Effects 0.000 claims description 7
- 230000006870 function Effects 0.000 claims description 7
- 238000002599 functional magnetic resonance imaging Methods 0.000 claims description 7
- 208000010125 myocardial infarction Diseases 0.000 claims description 7
- 238000002610 neuroimaging Methods 0.000 claims description 7
- 230000007170 pathology Effects 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 230000002829 reductive effect Effects 0.000 claims description 7
- 210000001519 tissue Anatomy 0.000 claims description 7
- AOYNUTHNTBLRMT-SLPGGIOYSA-N 2-deoxy-2-fluoro-aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](F)C=O AOYNUTHNTBLRMT-SLPGGIOYSA-N 0.000 claims description 6
- 206010008025 Cerebellar ataxia Diseases 0.000 claims description 6
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 6
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 6
- 208000006011 Stroke Diseases 0.000 claims description 6
- 239000000443 aerosol Substances 0.000 claims description 6
- 239000000090 biomarker Substances 0.000 claims description 6
- 230000006999 cognitive decline Effects 0.000 claims description 6
- 230000003920 cognitive function Effects 0.000 claims description 6
- 230000002496 gastric effect Effects 0.000 claims description 6
- 230000005802 health problem Effects 0.000 claims description 6
- 230000006386 memory function Effects 0.000 claims description 6
- 206010027175 memory impairment Diseases 0.000 claims description 6
- 230000002269 spontaneous effect Effects 0.000 claims description 6
- 206010001497 Agitation Diseases 0.000 claims description 5
- 206010002383 Angina Pectoris Diseases 0.000 claims description 5
- 102000014461 Ataxins Human genes 0.000 claims description 5
- 108010078286 Ataxins Proteins 0.000 claims description 5
- 208000002330 Congenital Heart Defects Diseases 0.000 claims description 5
- 206010013142 Disinhibition Diseases 0.000 claims description 5
- 208000009525 Myocarditis Diseases 0.000 claims description 5
- 206010033799 Paralysis Diseases 0.000 claims description 5
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims description 5
- 210000001367 artery Anatomy 0.000 claims description 5
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims description 5
- 230000030833 cell death Effects 0.000 claims description 5
- 210000003169 central nervous system Anatomy 0.000 claims description 5
- 235000012000 cholesterol Nutrition 0.000 claims description 5
- 208000028831 congenital heart disease Diseases 0.000 claims description 5
- 230000008021 deposition Effects 0.000 claims description 5
- 238000003745 diagnosis Methods 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 210000003061 neural cell Anatomy 0.000 claims description 5
- 239000000700 radioactive tracer Substances 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- 230000011273 social behavior Effects 0.000 claims description 5
- 210000002784 stomach Anatomy 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 238000004448 titration Methods 0.000 claims description 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 4
- 208000000044 Amnesia Diseases 0.000 claims description 4
- 208000031091 Amnestic disease Diseases 0.000 claims description 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 4
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 4
- 206010003805 Autism Diseases 0.000 claims description 4
- 208000020706 Autistic disease Diseases 0.000 claims description 4
- 208000020925 Bipolar disease Diseases 0.000 claims description 4
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 4
- 208000029812 Cerebral Small Vessel disease Diseases 0.000 claims description 4
- 206010067466 Cerebral microangiopathy Diseases 0.000 claims description 4
- 206010012218 Delirium Diseases 0.000 claims description 4
- 206010012239 Delusion Diseases 0.000 claims description 4
- 206010012335 Dependence Diseases 0.000 claims description 4
- 201000010374 Down Syndrome Diseases 0.000 claims description 4
- 206010014561 Emphysema Diseases 0.000 claims description 4
- 208000024412 Friedreich ataxia Diseases 0.000 claims description 4
- 208000015872 Gaucher disease Diseases 0.000 claims description 4
- 208000004547 Hallucinations Diseases 0.000 claims description 4
- 208000010496 Heart Arrest Diseases 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- 208000026680 Metabolic Brain disease Diseases 0.000 claims description 4
- 208000005314 Multi-Infarct Dementia Diseases 0.000 claims description 4
- 208000010428 Muscle Weakness Diseases 0.000 claims description 4
- 206010028372 Muscular weakness Diseases 0.000 claims description 4
- 206010036105 Polyneuropathy Diseases 0.000 claims description 4
- 206010037423 Pulmonary oedema Diseases 0.000 claims description 4
- 206010040070 Septic Shock Diseases 0.000 claims description 4
- 206010048327 Supranuclear palsy Diseases 0.000 claims description 4
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 4
- 230000001594 aberrant effect Effects 0.000 claims description 4
- 230000007000 age related cognitive decline Effects 0.000 claims description 4
- 238000013019 agitation Methods 0.000 claims description 4
- 230000006986 amnesia Effects 0.000 claims description 4
- 208000007502 anemia Diseases 0.000 claims description 4
- 230000000740 bleeding effect Effects 0.000 claims description 4
- 206010008129 cerebral palsy Diseases 0.000 claims description 4
- 210000004298 cerebral vein Anatomy 0.000 claims description 4
- 230000027288 circadian rhythm Effects 0.000 claims description 4
- 230000019771 cognition Effects 0.000 claims description 4
- 238000004891 communication Methods 0.000 claims description 4
- 230000003247 decreasing effect Effects 0.000 claims description 4
- 230000006735 deficit Effects 0.000 claims description 4
- 230000003412 degenerative effect Effects 0.000 claims description 4
- 231100000868 delusion Toxicity 0.000 claims description 4
- 239000006185 dispersion Substances 0.000 claims description 4
- 206010015037 epilepsy Diseases 0.000 claims description 4
- 238000013265 extended release Methods 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 150000002339 glycosphingolipids Chemical class 0.000 claims description 4
- 210000003709 heart valve Anatomy 0.000 claims description 4
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 201000007272 intracranial sinus thrombosis Diseases 0.000 claims description 4
- 208000028867 ischemia Diseases 0.000 claims description 4
- 230000008449 language Effects 0.000 claims description 4
- 230000002132 lysosomal effect Effects 0.000 claims description 4
- 208000024714 major depressive disease Diseases 0.000 claims description 4
- 201000004792 malaria Diseases 0.000 claims description 4
- 230000036244 malformation Effects 0.000 claims description 4
- 230000015654 memory Effects 0.000 claims description 4
- 230000036651 mood Effects 0.000 claims description 4
- 208000021090 palsy Diseases 0.000 claims description 4
- 208000008494 pericarditis Diseases 0.000 claims description 4
- 230000007824 polyneuropathy Effects 0.000 claims description 4
- 208000005333 pulmonary edema Diseases 0.000 claims description 4
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 4
- 230000000541 pulsatile effect Effects 0.000 claims description 4
- 210000002254 renal artery Anatomy 0.000 claims description 4
- 201000000980 schizophrenia Diseases 0.000 claims description 4
- 230000036303 septic shock Effects 0.000 claims description 4
- 230000001568 sexual effect Effects 0.000 claims description 4
- 230000035939 shock Effects 0.000 claims description 4
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 230000009529 traumatic brain injury Effects 0.000 claims description 4
- 230000003936 working memory Effects 0.000 claims description 4
- 206010000125 Abnormal dreams Diseases 0.000 claims description 3
- 206010010904 Convulsion Diseases 0.000 claims description 3
- 241000557626 Corvus corax Species 0.000 claims description 3
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims description 3
- 208000001953 Hypotension Diseases 0.000 claims description 3
- 206010071176 Impaired reasoning Diseases 0.000 claims description 3
- 206010029412 Nightmare Diseases 0.000 claims description 3
- 206010039740 Screaming Diseases 0.000 claims description 3
- 201000001880 Sexual dysfunction Diseases 0.000 claims description 3
- 208000010340 Sleep Deprivation Diseases 0.000 claims description 3
- 206010041235 Snoring Diseases 0.000 claims description 3
- 206010041349 Somnolence Diseases 0.000 claims description 3
- 208000008784 apnea Diseases 0.000 claims description 3
- 230000004706 cardiovascular dysfunction Effects 0.000 claims description 3
- 230000003931 cognitive performance Effects 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 235000009508 confectionery Nutrition 0.000 claims description 3
- 238000010411 cooking Methods 0.000 claims description 3
- 230000002996 emotional effect Effects 0.000 claims description 3
- 208000013403 hyperactivity Diseases 0.000 claims description 3
- 230000036543 hypotension Effects 0.000 claims description 3
- 208000018879 impaired coordination Diseases 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 210000000936 intestine Anatomy 0.000 claims description 3
- 230000007787 long-term memory Effects 0.000 claims description 3
- 230000018984 mastication Effects 0.000 claims description 3
- 238000010077 mastication Methods 0.000 claims description 3
- 230000006996 mental state Effects 0.000 claims description 3
- 230000004973 motor coordination Effects 0.000 claims description 3
- 201000003631 narcolepsy Diseases 0.000 claims description 3
- 230000003557 neuropsychological effect Effects 0.000 claims description 3
- 238000011056 performance test Methods 0.000 claims description 3
- 208000027232 peripheral nervous system disease Diseases 0.000 claims description 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 231100000872 sexual dysfunction Toxicity 0.000 claims description 3
- 230000006403 short-term memory Effects 0.000 claims description 3
- 210000000813 small intestine Anatomy 0.000 claims description 3
- 230000002485 urinary effect Effects 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 description 62
- 241000699670 Mus sp. Species 0.000 description 17
- 210000000988 bone and bone Anatomy 0.000 description 17
- 241000282472 Canis lupus familiaris Species 0.000 description 14
- 238000002600 positron emission tomography Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 210000003016 hypothalamus Anatomy 0.000 description 10
- 230000000979 retarding effect Effects 0.000 description 8
- 230000003442 weekly effect Effects 0.000 description 8
- 241000282412 Homo Species 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 238000002591 computed tomography Methods 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000000977 initiatory effect Effects 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000007850 degeneration Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000002604 ultrasonography Methods 0.000 description 5
- 201000004569 Blindness Diseases 0.000 description 4
- 206010061818 Disease progression Diseases 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000003466 anti-cipated effect Effects 0.000 description 4
- 210000004958 brain cell Anatomy 0.000 description 4
- 238000000151 deposition Methods 0.000 description 4
- 230000005750 disease progression Effects 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 210000002745 epiphysis Anatomy 0.000 description 4
- 230000002267 hypothalamic effect Effects 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 210000002161 motor neuron Anatomy 0.000 description 4
- 210000003928 nasal cavity Anatomy 0.000 description 4
- -1 phosphate ester Chemical class 0.000 description 4
- 210000000278 spinal cord Anatomy 0.000 description 4
- 229950004499 trodusquemine Drugs 0.000 description 4
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 241000251730 Chondrichthyes Species 0.000 description 3
- 108700011259 MicroRNAs Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 3
- UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 206010044565 Tremor Diseases 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 3
- 210000003403 autonomic nervous system Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 230000035771 neuroregeneration Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229950001248 squalamine Drugs 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 230000002123 temporal effect Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 230000004393 visual impairment Effects 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 2
- 208000019505 Deglutition disease Diseases 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000002740 Muscle Rigidity Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102000029797 Prion Human genes 0.000 description 2
- 108091000054 Prion Proteins 0.000 description 2
- 208000009106 Shy-Drager Syndrome Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 241001423892 Somniosus microcephalus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 102000019355 Synuclein Human genes 0.000 description 2
- 108050006783 Synuclein Proteins 0.000 description 2
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 description 2
- 206010046543 Urinary incontinence Diseases 0.000 description 2
- 206010047571 Visual impairment Diseases 0.000 description 2
- 210000003489 abdominal muscle Anatomy 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 102000003802 alpha-Synuclein Human genes 0.000 description 2
- 108090000185 alpha-Synuclein Proteins 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 210000003010 carpal bone Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- 231100000867 compulsive behavior Toxicity 0.000 description 2
- 238000013170 computed tomography imaging Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 229960001021 lactose monohydrate Drugs 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- 210000004558 lewy body Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 208000027061 mild cognitive impairment Diseases 0.000 description 2
- 230000003880 negative regulation of appetite Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 210000003487 olivary nucleus Anatomy 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000003319 supportive effect Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 102000013498 tau Proteins Human genes 0.000 description 2
- 108010026424 tau Proteins Proteins 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 208000029257 vision disease Diseases 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 208000000187 Abnormal Reflex Diseases 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- 244000303258 Annona diversifolia Species 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 102000007371 Ataxin-3 Human genes 0.000 description 1
- 108010032947 Ataxin-3 Proteins 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 238000011723 B6D2F1 (BDF1) mouse Methods 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010062746 Carditis Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700114 Chinchillidae Species 0.000 description 1
- 206010009696 Clumsiness Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 102000014824 Crystallins Human genes 0.000 description 1
- 108010064003 Crystallins Proteins 0.000 description 1
- 102100028188 Cystatin-F Human genes 0.000 description 1
- 101710169749 Cystatin-F Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 208000003164 Diplopia Diseases 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Natural products CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 241000282818 Giraffidae Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 208000002569 Machado-Joseph Disease Diseases 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- 241000283080 Proboscidea <mammal> Species 0.000 description 1
- 241000287530 Psittaciformes Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 206010067672 Spasmodic dysphonia Diseases 0.000 description 1
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 1
- 241000782099 Squaliformes Species 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000034799 Tauopathies Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047531 Visual acuity reduced Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical compound CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 description 1
- 229960005164 acesulfame Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 150000001279 adipic acids Chemical class 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Chemical class 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 208000007474 aortic aneurysm Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000013108 autonomic testing Methods 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000008372 bubblegum flavor Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- OCHFNTLZOZPXFE-JEDNCBNOSA-N carbonic acid;(2s)-2,6-diaminohexanoic acid Chemical compound OC(O)=O.NCCCC[C@H](N)C(O)=O OCHFNTLZOZPXFE-JEDNCBNOSA-N 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000005229 chemical vapour deposition Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000037998 chronic venous disease Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000013044 corticobasal degeneration disease Diseases 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000013229 diet-induced obese mouse Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- RRPFCKLVOUENJB-UHFFFAOYSA-L disodium;2-aminoacetic acid;carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O.NCC(O)=O RRPFCKLVOUENJB-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 208000029444 double vision Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 1
- 230000000632 dystonic effect Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000001353 entorhinal cortex Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 210000001097 facial muscle Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002082 fibula Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 150000002238 fumaric acids Chemical class 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 206010020745 hyperreflexia Diseases 0.000 description 1
- 230000035859 hyperreflexia Effects 0.000 description 1
- 208000015210 hypertensive heart disease Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000021646 inflammation of heart layer Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000015978 inherited metabolic disease Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- HXWLAJVUJSVENX-HFIFKADTSA-N ioflupane I(123) Chemical compound C1([C@H]2C[C@@H]3CC[C@@H](N3CCCF)[C@H]2C(=O)OC)=CC=C([123I])C=C1 HXWLAJVUJSVENX-HFIFKADTSA-N 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 208000018883 loss of balance Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000010339 medical test Methods 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 210000000236 metacarpal bone Anatomy 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 210000004237 neck muscle Anatomy 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 229940052345 onzetra Drugs 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 210000001152 parietal lobe Anatomy 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 208000030613 peripheral artery disease Diseases 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 230000007542 postnatal development Effects 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000007101 progressive neurodegeneration Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000008786 sensory perception of smell Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 201000002849 spasmodic dystonia Diseases 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 150000003431 steroids Chemical group 0.000 description 1
- 208000003755 striatonigral degeneration Diseases 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 150000003444 succinic acids Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 210000001137 tarsal bone Anatomy 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000000623 ulna Anatomy 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 230000021542 voluntary musculoskeletal movement Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862684496P | 2018-06-13 | 2018-06-13 | |
| US62/684,496 | 2018-06-13 | ||
| PCT/US2019/036946 WO2019241503A1 (en) | 2018-06-13 | 2019-06-13 | Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2019285065A1 true AU2019285065A1 (en) | 2021-01-07 |
Family
ID=68838925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019285065A Abandoned AU2019285065A1 (en) | 2018-06-13 | 2019-06-13 | Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20190381071A1 (https=) |
| EP (1) | EP3806862A4 (https=) |
| JP (1) | JP2021527090A (https=) |
| KR (1) | KR20210009422A (https=) |
| CN (1) | CN112566641A (https=) |
| AU (1) | AU2019285065A1 (https=) |
| BR (1) | BR112020025296A2 (https=) |
| CA (1) | CA3103463A1 (https=) |
| MX (1) | MX2020013614A (https=) |
| SG (1) | SG11202012343TA (https=) |
| WO (1) | WO2019241503A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12257068B2 (en) | 2020-05-29 | 2025-03-25 | Beijing Boe Health Technology Co., Ltd. | Sleep monitoring method and apparatus, sleep aid device and method |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11464789B2 (en) | 2018-08-03 | 2022-10-11 | Enterin, Inc. | Aminosterol compositions and methods of using the same for treating schizophrenia |
| EP3829587A4 (en) * | 2018-08-03 | 2022-07-20 | Enterin, Inc. | COMPOSITIONS AND METHODS FOR TREATMENT OF BRAIN AND GUESS DISORDERS |
| WO2020028791A1 (en) * | 2018-08-03 | 2020-02-06 | Enterin Laboratories | Low dosage intranasal aminosterol dosage forms and methods of using the same |
| CN110827282B (zh) * | 2020-01-13 | 2020-04-10 | 南京慧脑云计算有限公司 | 一种基于磁共振成像的脑白质纤维束示踪分析方法及系统 |
| CN111110873A (zh) * | 2020-02-24 | 2020-05-08 | 苏州欣影生物医药技术有限公司 | 一种磁共振/核医学双模态分子影像探针的制备方法 |
| WO2022244929A1 (ko) * | 2021-05-21 | 2022-11-24 | 애니머스큐어 주식회사 | 이노토디올을 포함하는 근육 질환의 예방 또는 치료용 조성물 |
| WO2025054408A1 (en) * | 2023-09-07 | 2025-03-13 | NeuroTherapia, Inc. | Methods of treating cognitive impairment |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6143738A (en) * | 1995-06-07 | 2000-11-07 | Magainin Pharmaceuticals, Inc. | Therapeutic uses for an aminosterol compound |
| JP2010538072A (ja) * | 2007-09-06 | 2010-12-09 | ジェナエラ コーポレイション | 糖尿病を治療する方法 |
| WO2011066260A2 (en) * | 2009-11-25 | 2011-06-03 | Michael Zasloff | Formulations comprising aminosterols |
| US10040817B2 (en) * | 2013-10-03 | 2018-08-07 | Enterin Laboratories, Inc. | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
-
2019
- 2019-06-13 AU AU2019285065A patent/AU2019285065A1/en not_active Abandoned
- 2019-06-13 US US16/440,414 patent/US20190381071A1/en not_active Abandoned
- 2019-06-13 EP EP19818961.5A patent/EP3806862A4/en not_active Withdrawn
- 2019-06-13 CN CN201980052151.2A patent/CN112566641A/zh active Pending
- 2019-06-13 US US17/251,322 patent/US20210252023A1/en not_active Abandoned
- 2019-06-13 MX MX2020013614A patent/MX2020013614A/es unknown
- 2019-06-13 CA CA3103463A patent/CA3103463A1/en active Pending
- 2019-06-13 JP JP2020569002A patent/JP2021527090A/ja active Pending
- 2019-06-13 WO PCT/US2019/036946 patent/WO2019241503A1/en not_active Ceased
- 2019-06-13 SG SG11202012343TA patent/SG11202012343TA/en unknown
- 2019-06-13 KR KR1020217000559A patent/KR20210009422A/ko not_active Ceased
- 2019-06-13 BR BR112020025296-4A patent/BR112020025296A2/pt not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12257068B2 (en) | 2020-05-29 | 2025-03-25 | Beijing Boe Health Technology Co., Ltd. | Sleep monitoring method and apparatus, sleep aid device and method |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019241503A1 (en) | 2019-12-19 |
| MX2020013614A (es) | 2021-05-27 |
| CN112566641A (zh) | 2021-03-26 |
| BR112020025296A2 (pt) | 2021-03-09 |
| JP2021527090A (ja) | 2021-10-11 |
| US20210252023A1 (en) | 2021-08-19 |
| EP3806862A4 (en) | 2022-07-06 |
| SG11202012343TA (en) | 2021-01-28 |
| EP3806862A1 (en) | 2021-04-21 |
| US20190381071A1 (en) | 2019-12-19 |
| KR20210009422A (ko) | 2021-01-26 |
| CA3103463A1 (en) | 2019-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210252023A1 (en) | Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration | |
| JP7312169B2 (ja) | 遺伝性てんかん性障害の処置に使用するガナキソロン | |
| JP6957602B2 (ja) | 神経変性疾患のための治療薬 | |
| US20260098052A1 (en) | Human aminosterol ent-03 compounds, related compositions comprising the same, and methods of using the same | |
| JP7757446B2 (ja) | リソソーム蓄積障害に関する医薬組成物及び使用 | |
| JP2021527090A5 (https=) | ||
| US20240277732A1 (en) | Compositions and methods for treating brain-gut disorders | |
| JP2012500801A (ja) | Ｃｎｓ疾患の治療法 | |
| US20190298740A1 (en) | Methods and compositions for treating hallucinations and conditions related to the same | |
| KR20200074170A (ko) | 신경퇴행성 질병에 대한 치료제 | |
| US20200129528A1 (en) | Methods for treating blood pressure conditions using aminosterol compositions | |
| WO2020028791A1 (en) | Low dosage intranasal aminosterol dosage forms and methods of using the same | |
| JP2016538269A (ja) | 筋ジストロフィーの処置のための方法 | |
| JPWO2019241503A5 (https=) | ||
| WO2023146838A1 (en) | Methods for treating or preventing neurodegenerative disease using a combination of aminosterols and an insulin compound | |
| US20200038413A1 (en) | Methods of treating parkinson's disease using aminosterol compositions | |
| Malaspina et al. | Disorders of the Motor Cells: The Motor Neuron Diseases | |
| KR20260023584A (ko) | 다발성 경화증의 치료를 위한 이보가인 | |
| US20200038418A1 (en) | Methods of treating autism spectrum disorder using aminosterol compositions | |
| Abe et al. | WFN15-1473 Movement Disorders Effects of zonisamide for overall non-motor symptoms with Parkinson’s disease patients | |
| Dahimene et al. | Genotype-phenotype correlations in a French cohort with Becker muscular dystrophy: focus on cognitive aspects | |
| BR112020007657B1 (pt) | Uso de leucina, acetil-leucina ou um sal farmaceuticamente aceitável da mesma para tratamento da síndrome das pernas inquietas (rls) | |
| JPWO2014088106A1 (ja) | 線維筋痛症の予防または治療薬 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |